Navigation Links
United Therapeutics Reports Fourth Quarter and Annual 2007 Financial Results
Date:2/19/2008

atements include our expectations and intentions regarding the payment of federal and state income taxes for 2007, the generation of taxable income, the availability and utilization of net operating loss carry forwards to reduce taxable income, and the availability, creation and utilization of research tax credits to pay income taxes that are based on our current beliefs and expectations as to future outcomes. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, which could cause actual results to differ materially from anticipated results. Consequently, such forward- looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and current reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Reform Act of 1995 for forward-looking statements. We are providing this information as of February 19, 2008, and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason.

Remodulin is a registered trademark of United Therapeutics Corporation.

OvaRex is a registered trademark of AltaRex Medical Corp.

UNITED THERAPEUTICS CORPORATION

CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data)

Three Months Ended Years Ending

December 31, December 31,

2007 2006 2007 2006

Revenues:

Net product sales
'/>"/>

SOURCE United Therapeutics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. United States Patent Office Grants CryoCors Request for Patent Interference
2. United Therapeutics to Announce Fourth Quarter and Annual 2007 Financial Results Before Market Open on Tuesday, February 19, 2008
3. Energy Conversion Devices and United Solar Ovonic Enter Into New $55 Million Secured Credit Facility Agreements
4. Nycomeds Ciclesonide to be Commercialised in the United States by Sepracor
5. Chindexs United Family Hospitals and Clinics and NBC Enter into Healthcare Services Agreement
6. Neptune Technologies receives GRAS notification in the United States
7. Essilor: New Acquisitions in the United States and Brazil
8. Neptune Technologies & Bioressources Inc. Secures Access to Nationwide Consumer Mass Market in the United States
9. Medical Services Begins Working With United States Companies for Distribution of Its Products
10. United Therapeutics Reports Third Quarter 2007 Financial Results
11. Bioponic Phytoceuticals to Roll Out Multiple Products to 1,000 Major Health Food Stores in the Western United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2015)... SEATTLE , May 20, 2015  Resolution Bioscience ... of ctDx ALK TM , a blood-based liquid ... non-small cell lung carcinoma (NSCLC), the most common form ... the test to guide patients to personalized therapies and ... sample. The Department of Health, the CLIA ...
(Date:5/20/2015)... TRIANGLE PARK, North Carolina , ... weltweit führende Unternehmen für klinische Logistik ... Finanzergebnisse für das Geschäftsjahr 2014, das ... und eingereicht. Das Unternehmen hat die ... Logo - http://photos.prnewswire.com/prnh/20110930/NY78064LOGO ...
(Date:5/20/2015)... (PRWEB) May 20, 2015 The ... based not-for-profit organization, is pleased to announce they are ... Trials Day. These donations represent the effort and commitment ... at the GGI partner sites in 2014. , ... the greater good of clinical trial participation, GGI supports ...
(Date:5/20/2015)... May 20, 2015  OncoSec Medical Inc. ("OncoSec") ... immunotherapies, will present data from ongoing clinical and ... Sciences, Emerging Approaches to Cancer Immunotherapy. OncoSec,s Chief ... and Chief Medical Officer Mai. H. Le, MD, ... Plasmid IL-12 Can Increase CD8 TILs and Drive ...
Breaking Biology Technology:Resolution Bioscience Receives CLIA Certification for its Diagnostic Laboratory and Launches CLIA-Certified Liquid Biopsy for Lung Cancer 2Marken schließt Ergebnisse für das Geschäftsjahr 2014 ab 2The Greater Gift Initiative Donates over 10,000 Vaccines in Honor of International Clinical Trials Day 2OncoSec Medical to Present Data at the New York Academy of Sciences' Cancer Immunotherapy Symposium 2OncoSec Medical to Present Data at the New York Academy of Sciences' Cancer Immunotherapy Symposium 3OncoSec Medical to Present Data at the New York Academy of Sciences' Cancer Immunotherapy Symposium 4
... and long-term disease-free survival of breast cancer patients; ... April 23 Clarient, Inc. ... anatomic pathology and molecular testing services resource for ... that it has been granted an exclusive intellectual ...
... , - Strong 10.3% Growth ... the world leader in ophthalmic optics, today,announced consolidated revenue of ... a reported 10.3% increase on the first quarter,of 2008. Excluding ... Despite contracting demand early in the ...
... today the opening,ceremony of its new active pharmaceutical ingredient ... to take over the site that,had been manufacturing Lipitor(R) ... April 6th and the transaction closed on the 8th; ... of manufacture for Pfizer but,will mostly make use of ...
Cached Biology Technology:Clarient Granted Exclusive License to Commercialize Breast Cancer Biomarker by Indiana University Research and Technology Corporation 2Clarient Granted Exclusive License to Commercialize Breast Cancer Biomarker by Indiana University Research and Technology Corporation 3Clarient Granted Exclusive License to Commercialize Breast Cancer Biomarker by Indiana University Research and Technology Corporation 4Clarient Granted Exclusive License to Commercialize Breast Cancer Biomarker by Indiana University Research and Technology Corporation 5Essilor : 2009 First Quarter Report 2Essilor : 2009 First Quarter Report 3Essilor : 2009 First Quarter Report 4Hovione Opens its New API Plant in Cork 2Hovione Opens its New API Plant in Cork 3
(Date:5/18/2015)... May 18, 2015 Fingerprint Cards (FPC) ... FPC1025, FPC1145, FPC1155 and FPC1035 from one if its module ... and including Q3 2015 and the sensors will be used ... order values for 2015 hereby amount to 740 MSEK to ... of 140 MSEK and a number of smaller orders not ...
(Date:5/11/2015)... 11, 2015 Curemark LLC, a privately held ... a new Phase III double blind, randomized, placebo-controlled clinical ... CM-AT, on all children ages 3-8 with Autism. Previously, ... III double blinded clinical trial for CM-AT in children ... the digestive enzyme chymotrypsin. This new trial will help ...
(Date:5/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... market, reminds investors and media that  Mr. David Tunnell ... SECURE CONNEXIONS AMERICA 2015, held in Washington DC ... conference is organized into a series of nine session tracks. ... Fraud: Where is the Trust in Cyberspace? and will ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
... September 5, 2013, Shenzhen, China BGI in collaboration ... other Chinese institutes, have completed the genome sequencing of ... infectious disease tuberculosis (TB). The study published online in ... researchers to better understand the genetic basis underlying drug ...
... industry and cities, coupled with a rising world shortage of ... increase in the use of treated wastewater for farming and ... -- comparable in North America alone to the volume of ... in many nations, not even quantified. Of ...
... Mexico, Rocky Mountain juniper ( Juniperus scopulorum Sarg .) ... The juniper,s woodhighly valued for its durability, rich color, ... furniture, and fence posts. For centuries, the leaves and ... essential oil, have been used extensively by native people ...
Cached Biology News:Drug resistance-associated genes: A cornerstone for the control and protection against tuberculosis 2UN: Rising reuse of wastewater in forecast but world lacks data on 'massive potential resource' 2UN: Rising reuse of wastewater in forecast but world lacks data on 'massive potential resource' 3UN: Rising reuse of wastewater in forecast but world lacks data on 'massive potential resource' 4UN: Rising reuse of wastewater in forecast but world lacks data on 'massive potential resource' 5UN: Rising reuse of wastewater in forecast but world lacks data on 'massive potential resource' 6UN: Rising reuse of wastewater in forecast but world lacks data on 'massive potential resource' 7UN: Rising reuse of wastewater in forecast but world lacks data on 'massive potential resource' 8UN: Rising reuse of wastewater in forecast but world lacks data on 'massive potential resource' 9
... The economical ICS-90 uses continuous chemical suppression ... give you fast, accurate determinations of common ... Easy to operate, quick to equilibrate, and ... compact ICS-90 helps you achieve maximum sample ...
... contains 400 unique human proteins on ... The proteins, a cross section of ... quadruplicate for high-quality results. Additional control ... guarantee high validity and reproducibility., ,UNIchip ...
... 400 unique human proteins on a ... proteins, all extracellular proteins (EP) according ... in quadruplicate for high-quality results. Additional ... layout guarantee high validity and reproducibility., ...
... stocks contained in standard 96-well microtiter plates. ... approximately 5,000 clones per plate. After positive ... the corresponding subplate is screened with a ... well(s). Cells from a positive well are ...
Biology Products: